MM is a common type of cancer that unfortunately leads to a significant number of deaths each year. The majority of the reported MM cases are detected in the advanced stages, posing significant challenges for treatment. Additionally, all MM patients eventually develop resistance or experience relapse; therefore, advances in treatment are needed. However, developing new anti-cancer drugs, especially for MM, requires significant financial investment and a lengthy development process. The study of drug repurposing involves exploring the potential of existing drugs for new therapeutic uses. This can significantly reduce both time and costs, which are typically a major concern for MM patients. The utilization of pre-existing non-cancer drugs for various myeloma treatments presents a highly efficient and cost-effective strategy, considering their prior preclinical and clinical development. The drugs have shown promising potential in targeting key pathways associated with MM progression and resistance. Thalidomide exemplifies the success that can be achieved through this strategy. This review delves into the current trends, the challenges faced by conventional therapies for MM, and the importance of repurposing drugs for MM. This review highlights a noncomprehensive list of conventional therapies that have potentially significant anti-myeloma properties and anti-neoplastic effects. Additionally, we offer valuable insights into the resources that can help streamline and accelerate drug repurposing efforts in the field of MM.
多发性骨髓瘤（MM）是一种常见的癌症类型，不幸的是每年导致大量死亡。大多数报告的MM病例在晚期才被检测出来，给治疗带来了重大挑战。此外，所有MM患者最终都会产生耐药性或经历复发；因此，治疗方面的进展是必要的。然而，开发新的抗癌药物，特别是针对MM的药物，需要大量的资金投入和漫长的开发过程。药物再利用研究涉及探索现有药物用于新治疗用途的潜力。这可以显著减少时间和成本，而这两者通常是MM患者主要关注的问题。考虑到已有的临床前和临床开发基础，利用现有的非癌症药物进行多发性骨髓瘤治疗是一种高效且具有成本效益的策略。这些药物在靶向与MM进展和耐药性相关的关键通路方面显示出有希望的潜力。沙利度胺的成功例证了通过这一策略可以取得的成就。本综述深入探讨了当前趋势、MM传统疗法面临的挑战以及药物再利用对MM的重要性。本综述重点介绍了一些具有潜在显著抗骨髓瘤特性和抗肿瘤作用的传统疗法，但并非详尽无遗。此外，我们还提供了有价值的见解，介绍了有助于简化和加速MM领域药物再利用工作的资源。
肿瘤(癌症)患者之家